These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29056249)

  • 1. NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome.
    Boumediene A; Vachin P; Sendeyo K; Oniszczuk J; Zhang SY; Henique C; Pawlak A; Audard V; Ollero M; Guigonis V; Sahali D
    J Autoimmun; 2018 Mar; 88():91-102. PubMed ID: 29056249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
    BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
    Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
    Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy.
    Chan CY; Teo S; Lu L; Chan YH; Lau PY; Than M; Jordan SC; Lam KP; Ng KH; Yap HK
    Transl Res; 2021 Sep; 235():48-61. PubMed ID: 33812063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.
    Fribourg M; Cioni M; Ghiggeri G; Cantarelli C; Leventhal JS; Budge K; Bin S; Riella LV; Colucci M; Vivarelli M; Angeletti A; Perin L; Cravedi P
    Front Immunol; 2021; 12():726428. PubMed ID: 34621271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells.
    Webendörfer M; Reinhard L; Stahl RAK; Wiech T; Mittrücker HW; Harendza S; Hoxha E
    Front Immunol; 2020; 11():586012. PubMed ID: 33628202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).
    C Willcocks L; Qian W; Cader R; Gatley K; Siddiqui H; Tabebisong E; Champion K; Kronbichler A; Lightstone L; Jayne D; Wilson E; Griffith M
    BMC Nephrol; 2024 Aug; 25(1):253. PubMed ID: 39112932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
    Munyentwali H; Bouachi K; Audard V; Remy P; Lang P; Mojaat R; Deschênes G; Ronco PM; Plaisier EM; Dahan KY
    Kidney Int; 2013 Mar; 83(3):511-6. PubMed ID: 23325085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults.
    Iwabuchi Y; Moriyama T; Itabashi M; Takei T; Nitta K
    Contrib Nephrol; 2018; 195():12-19. PubMed ID: 29734146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease.
    Iwabuchi Y; Miyabe Y; Makabe S; Nakano M; Manabe S; Karasawa K; Moriyama T; Nitta K
    Medicine (Baltimore); 2018 Oct; 97(42):e12704. PubMed ID: 30334956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mycophenolate mofetil versus cyclosporine A in children with primary refractory nephrotic syndrome].
    Geng HY; Ji LN; Chen CY; Tu J; Li HR; Bao R; Lin Y
    Zhonghua Er Ke Za Zhi; 2018 Sep; 56(9):651-656. PubMed ID: 30180402
    [No Abstract]   [Full Text] [Related]  

  • 16. Altered invariant natural killer T cell subsets and its functions in patients with oral squamous cell carcinoma.
    Singh AK; Shukla NK; Das SN
    Scand J Immunol; 2013 Nov; 78(5):468-77. PubMed ID: 23980793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome.
    Casiraghi F; Todeschini M; Podestà MA; Mister M; Ruggiero B; Trillini M; Carrara C; Diadei O; Villa A; Benigni A; Remuzzi G
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
    Katsuno T; Masuda T; Saito S; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Kitamura H; Tsuzuki T; Ito Y; Maruyama S
    Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome.
    Sawara Y; Itabashi M; Kojima C; Tabata H; Kamei D; Kawanishi K; Moriyama T; Sugiura H; Tsukada M; Takei T; Ogawa T; Yoshida T; Arai J; Uchida K; Tsuchiya K; Nitta K
    Clin Nephrol; 2009 Jul; 72(1):69-72. PubMed ID: 19640390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.